Studies have shown that dysregulation of MET signaling pathway including gene amplification, overexpression of the ligand and/or receptor, autocrine signaling, and paracrine signaling has been indicated as a cancer-associated mechanism [4,5,6,7]. This evidence concerns the gene MET and cancer.